Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study.
Molecules
; 26(6)2021 Mar 17.
Article
in English
| MEDLINE | ID: covidwho-1138745
ABSTRACT
The COVID-19 outbreak continues to spread worldwide at a rapid rate. Currently, the absence of any effective antiviral treatment is the major concern for the global population. The reports of the occurrence of various point mutations within the important therapeutic target protein of SARS-CoV-2 has elevated the problem. The SARS-CoV-2 main protease (Mpro) is a major therapeutic target for new antiviral designs. In this study, the efficacy of PF-00835231 was investigated (a Mpro inhibitor under clinical trials) against the Mpro and their reported mutants. Various in silico approaches were used to investigate and compare the efficacy of PF-00835231 and five drugs previously documented to inhibit the Mpro. Our study shows that PF-00835231 is not only effective against the wild type but demonstrates a high affinity against the studied mutants as well.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Protease Inhibitors
/
Pyrrolidinones
/
Coronavirus 3C Proteases
/
Indoles
/
Leucine
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal subject:
Biology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS